Linda Chang1, Sara Hayama1, Steven Buchthal1, Chathura Siriwardhana1, Daniel Alicata1, Zachary Pang1, Tricia Wright1, Jon Skranes2, and Thomas Ernst1
1University of Hawaii at Manoa, Honolulu, HI, United States, 2Pediatrics, Sorlandet Hospital, Arendal, Norway
Synopsis
In prior
studies, children with prenatal methamphetamine-(PME) or tobacco-exposure (PTE)
showed elevated brain metabolites levels.
The current study evaluated infants with PME and PTE during the first 5
months of life and found abnormal developmental trajectories of metabolites in
the frontal white matter, with abnormally lower levels of total creatine [tCr],
N-acetylaspartate [NAA], and glumate+glutamine [Glx] at baseline, and steeper
developmental trajectories that resulted in normal or elevated levels after
2-months old. Furthermore, the trajectories of basal ganglia-[NAA] and
corticospinal tract-[tCr] further contributed to the slower muscle tone
development in PME infants, especially the males.
INTRODUCTION
Methamphetamine (Meth) is the second-most
commonly abused category of illicit drugs worldwide.1 Although
70-90% of Meth-users smoke tobacco cigarettes concurrently,2 the
impact of comorbid Meth and tobacco-use during pregnancy on fetal brain
development is rarely studied. Therefore,
we evaluated whether the developmental trajectories of brain metabolites are altered
in neonates with prenatal Meth+tobacco-exposure (PME) or prenatal tobacco-exposure
(PTE) during the first 5 months of life using 1H-MR spectroscopy (1H-MRS).METHODS
170 healthy neonates [85 unexposed (52.9% female), 42 PME (57.1% female), 43 PTE (34.9% female)] fulfilling study criteria were scanned 1-5 times over the first 5 months at 3 Tesla (Siemens TIM Trio). 1H-MRS was performed using PRESS (TR/TE=3000/30ms) in 5 brain regions (Fig. 1), measuring the T2 decay of water at 10 TE-values to correct for CSF partial volumes. Data were processed using LCModel3 to determine concentrations of N-acetyl aspartate (NAA), choline (Cho), total creatine (tCr), glutamate +glutamine (Glx), and myo-inositol (mI). The infants were also evaluated serially with Amiel-Tison Neurological Assessment at Term (ATNAT). Mixed model repeated-measures ANCOVAs were performed to assess group differences in metabolite development and ATNAT scores. Postmenstrual age (PMA), PMA2, sex, and Index of Social Position (ISP) were included as covariates. P<0.05 were considered significant for group effects and group interactions.RESULTS
Participant characteristics:
The mothers had similar ages at delivery (PME: 28.5±1.0 years; PTE: 26.3±0.8 years;
Unexposed: 28.3±0.7 years), but PME mothers had greater pregnancy weight gain (20.5±1.6kg)
than PTE (14.2±1.6kg) and Unexposed (14.4±0.7) mothers, p<0.0007. Additionally, compared to Unexposed mothers,
PME and PTE mothers had lower index of social position (ISP: 63.7±1.0 and
52.7±2.1 vs. 44.2±1.6; p<0.001). During
pregnancy, PME mothers cumulatively used 78±16g Meth and smoked more tobacco
cigarettes (2,250±360) than PTE mothers (1,190±200). At birth, the three
neonate groups were similar in gestational ages (PME: 39.1±0.2weeks; PTE: 39.2±0.2weeks;Unexposed: 39.3±0.2weeks), but the PME group had lower BMI
(12.3±0.2) compared to PTE (12.9±0.2) and Unexposed (13.1±0.1); p=0.01. At baseline imaging, the neonates were
similar PMA (PME:42.9±0.7weeks; PTE:42.1±0.5weeks; Unexposed:41.5±0.3weeks),
p=0.09. The baseline ATNAT showed poorer
total scores and weaker muscle tone in the PME neonates (4.0±0.4) compared to PTE (2.9±0.3) and Unexposed
neonates (3.0±0.1), p=0.02, but these group differences were no longer
significant by 3-months of age (Fig. 2).
1H-MRS: Most brain metabolites showed age-dependent changes (p<0.05–0.001); therefore, PMA was included in final models. Fig. 3 shows that compared to PTE and Unexposed neonates, PME neonates had lower initial levels of FWM-[tCr], FWM-[Glx], thalamic-[Cho], and thalamic-[NAA]. However, these metabolite values normalized or increased to above normal after 48 weeks PMA. In Fig. 4, [mI] was lower in girls than boys in both BG (Sex: p=0.01) and ACC (Sex: p=0.03). CST-[mI] was lowest in PTE and highest in PME infants (Group: p=0.002) and tended to be lower in girls than boys (Sex: p=0.08). Additionally, group effects differed between sexes for FWM-[mI] (Group×Sex:p=0.03) and ACC-[tCr] (Group×Sex: p=0.045). Furthermore, PME infants showed altered development of FWM-Cho] in a sex-specific manner, with lower levels initially and lack of normal age-dependent decreases (Group×Sex×PMA: p=0.014; Group: p=0.034). Lastly, BG-[NA] further mediated the effects of PMA and PME on the abnormal muscle tone development by a multiplicative factor 1.046 (95%CI:1.004,1.110), while CST-[tCr] mediated the gender effect (being male) by a multiplicative factor 1.052 (95%CI:1.003,1.130), Fig. 5.
DISCUSSION:
During
the first few months of life, the brain grows rapidly4,5 and our
infants showed rapid age-dependent changes in brain metabolite concentrations. Although
PME infants showed abnormally low levels of [tCr], [NAA], and [Glx] in FWM at baseline,
their steeper developmental trajectories resulted in normal or elevated levels after
2-months old. The elevated brain metabolites at older age and the sex-specific
effects are consistent with those found in prior 1H-MRS studies of PME
children,6 including those at 3-4 years of age.7 These
findings also complement altered DTI measures in PME infants,5 and are
consistent with preclinical studies of prenatal Meth or Nicotine-exposure that
led to aberrant axonal development with increased spine densities and altered myelin
gene-expression.8,9 Collectively, our findings suggest that PME, both
Meth and tobacco, was associated with altered neonatal neuronal and glial
development, which might have resulted from epigenetic influences such as those
found in rodents with prenatal Meth-exposure10 or prenatal nicotine-exposure.11
Finally, the abnormal BG-[NA] development contributed to the delayed muscle
tone development in PME infants, while the gender effect mediated through
CST-[tCr] slightly delayed the muscle tone development for boys. Longitudinal
follow-up evaluations of our cohort are needed to better understand the impact of prenatal
drug exposure on neurological development.Acknowledgements
Grant
support from the NIH (U54-NS56883, K24-DA16170, K02-DA16991, G12-MD003061) and ONDCP
(DABK39-03-C-0060); infrastructure support from the Queen’s Medical Center. We
also thank our research participants, as well as the many technical and
clinical staff at the Neuroscience and MR Research Program at the John A. Burns School of Medicine for their assistance
with data collection and processing.References
1)
United Nations Office on Drugs and Crime 2014, sales
No. E.14.XI.7. 2) Weinberger AH &
Sofuoglu M. Amer J Drug Alcohol Abuse 2009;35(1):12-17. 3) Provencher S. Magn Reson Med
1993;30:672. 4) Holland D et al. JAMA Neurology 2014; 71(10):1266-1274. 5) Chang L et al. JAMA Psychiatry 2016
Epub. 6) Smith L et al. Neurology
2001;67:255-260; 7) Chang L et al. NeuroImage 2009; 48(2):391-397. 8) Mychasiuk
et al. Brain Res 2013;1499:53-60. 9) Cao et al. Transl Psychiatry
2013;3:e247. 10) Itzhak et al. Mol Psychiatry 2015;20(2)232-239. 11)
Jung et al. Nat Neurosci 2016;19(7):905-914.